NCT07409272 2026-04-16
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
170 trialsNCT06593431 2026-04-15
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07522073 2026-04-13
DAWN-303
Incyte Corporation
Phase 3 Recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT07252232 2026-04-06
RASolute 304
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT07491445 2026-04-06
RASolute 303
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT06608927 2026-04-01
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06807437 2026-03-31
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06998940 2026-03-27
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
NCT05836870 2026-03-02
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT05720338 2026-02-19
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Case Comprehensive Cancer Center
Phase 3 Recruiting
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT04340141 2026-02-10
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT06861088 2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3 Recruiting
NCT07272109 2025-12-15
PTCA199-16
Fudan University
Phase 3 Not yet recruiting
NCT06625320 2025-12-12
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT03269994 2025-10-21
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT02000089 2025-10-09
CAPS5
Johns Hopkins University
Phase 3 Recruiting
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07155525 2025-09-18
NBCA-MS
Minia University
Phase 3 Recruiting
NCT05680870 2025-09-09
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
Tanta University
Phase 3 Completed
NCT07081360 2025-08-29
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University
Phase 3 Recruiting
NCT07138846 2025-08-24
A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
Shanghai Miracogen Inc.
Phase 3 Not yet recruiting
NCT07066098 2025-08-15
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Recruiting
NCT03434678 2025-07-30
Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT06897644 2025-05-25
PANThEON
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT00806611 2025-05-15
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
Thomas Jefferson University
Phase 3 Completed
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT06332274 2025-05-13
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT03468335 2025-04-17
PREDICT
AIO-Studien-gGmbH
Phase 3 Completed
NCT03984214 2025-04-10
Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 3 Completed
NCT04229004 2025-04-06
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Pancreatic Cancer Action Network
Phase 3 Completed
NCT02457156 2025-03-13
PANasta
University of Liverpool
Phase 3 Completed
NCT03899636 2025-02-12
DIRECT
Angiodynamics, Inc.
Phase 3 Active not recruiting
NCT02349412 2025-02-07
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT06427447 2025-02-04
ADJUPANC
Changhai Hospital
Phase 3 Recruiting
NCT06714604 2024-12-03
ADVANTAGE
Sahlgrenska University Hospital
Phase 3 Recruiting
NCT05744219 2024-10-21
IRIS
Uppsala University Hospital
Phase 3 Recruiting
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT01231347 2024-07-16
GAMMA
NantCell, Inc.
Phase 3 Completed
NCT06391892 2024-04-30
LIQUIPANC
Elisabethinen Hospital
Phase 3 Recruiting
NCT01827553 2024-04-11
CONKO-007
University of Erlangen-Nürnberg Medical School
Phase 3 Completed
NCT02395016 2024-04-04
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT06346366 2024-04-04
PANORAMA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Unknown
NCT04674956 2024-04-02
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
Phase 3 Unknown